FAOAI
RXRX icon

Fund Advisors of America Inc’s Recursion Pharmaceuticals RXRX Stock Holding History

Fund Advisors of America Inc’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.6K Sell
12,152
-5,792
-32% -$19.3K 0.04% 120
2026
Q1 		$55.1K Sell
17,944
-2,211
-11% -$8.54K 0.06% 118
2025
Q4 		$82.4K Buy
+20,155
New +$99.8K 0.08% 119

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Fund Advisors of America Inc's RXRX Position: Q2 2026 in Review

Fund Advisors of America Inc reduced its Recursion Pharmaceuticals (RXRX) stake by 32% in Q2 2026, selling an estimated $19.3K and leaving 12,152 shares worth $44.6K. The position accounts for 0.04% of the portfolio, ranked #120.

Fund Advisors of America Inc first reported a position in RXRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $82.4K in Q4 2025. 320 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Fund Advisors of America Inc held 12,152 shares of Recursion Pharmaceuticals worth $44.6K as of Q2 2026.
  • Fund Advisors of America Inc sold 5,792 Recursion Pharmaceuticals shares in Q2 2026, an estimated $19.3K.
  • Recursion Pharmaceuticals made up 0.04% of Fund Advisors of America Inc's portfolio in Q2 2026, its #120 holding.
  • Fund Advisors of America Inc first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Fund Advisors of America Inc's Recursion Pharmaceuticals position peaked at $82.4K in Q4 2025.
  • 320 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Fund Advisors of America Inc's 13F filing for Q2 2026, filed 11 Aug 2026.